| 张培彤,于明薇,杨宗艳,李道睿,刘永衡,林洪生.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].,2010,30(7):702-705 |
| 中晚期非小细胞肺癌中西医疗效评价方法比较研究 |
| Comparative Study on the Methods of Chinese Medicine and Western Medicine Therapeutic Evaluation for Advanced Non-small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 疗效评价 非小细胞肺癌 中医药 |
| 英文关键词:therapeutic evaluation non-small cell lung cancer Chinese medicine |
| 基金项目:首都医学创新发展科研基金资助项目(No.03-Ⅱ-06) |
|
| Hits: 1461 |
| Download times: 1102 |
| 中文摘要: |
| 目的比较中医及西医两种疗效评价方法在中晚期非小细胞肺癌应用中的差异和特点。方法3个分中心共纳入中晚期非小细胞肺癌患者200例,分为2组:中药组104例采用中药注射剂联合辨证论治汤剂治疗,化疗组96例采用国际通用的化疗方案治疗,疗程均为6周。以包含临床症状、瘤体、卡式评分、体重、免疫功能评价的"中医治疗中晚期肺癌患者临床受益(疗效)评定标准"和WHO实体瘤疗效评价标准同步进行疗效观察。结果按照WHO实体瘤疗效评价标准评价,化疗组疗效明显优于中药组(P<0.01);按照"中医治疗中晚期肺癌患者临床受益(疗效)评定标准"评价,中药组优于化疗组,二组比较显示出有出现统计学意义的趋势(P=0.05);上述两种评价方法得出的结论存在差异。结论"中医治疗中晚期肺癌患者临床受益(疗效)评定标准"与WHO实体瘤疗效评价标准相比更能反映中医药治疗肿瘤的特色与优势,具有进一步研究的价值。 |
| 英文摘要: |
| Objective To compare the differences and characteristics in Chinese medicine(CM)and Western medicine therapeutic evaluation methods in the application of advanced non-small cell lung cancer.Methods A total of 200 cases of advanced non-small cell lung cancer from 3 subcenters were enrolled the study and assigned to two groups,104 in the CM group treated with CM injection combined with treatment based on syndrome differentiation,96 in the chemotherapy group treated with the international chemothearapy scheme,both the course of treatment was 6 weeks.Their short-term therapeutic effects were observed by the"clinic efficacy appraisal standard of therapy for advanced lung cancer with CM"simultaneously and by the follow-up Western medical solid tumor’s effect evaluation criterion,including clinical symptoms,tumor body,Karnorfsky score,body weight and immune function evaluation.Results According to WHO solid tumor’s effect evaluation criterion,the efficacy of the chemotherapy group was much better than that of the CM group(P<0.01).While,according to the"clinic efficacy appraisal standard of therapy for advanced lung cancer with CM",the efficacy of the CM group was better than that of the chemotherapy group without statistical difference(P=0.05),however,there was a very strong trend of appearing difference.There was difference in the results of the two evaluation methods.Conclusion Compared with WHO solid tumor’s effect evaluation criterion,"the clinic efficacy appraisal standard of therapy for advanced lung cancer with CM"can reflect more features and advantages of CM for cancer treatment,having value for further study. |
| View Full Text View/Add Comment Download reader |
|
|
|
